Listed bottle
15 mL at 300 mg/mL
Renewal
No automatic renewal advertised
Regulatory status
Compounded; not FDA-approved

The bottle behind the advertised price

GobyMeds lists its NAD+ nasal spray at $199 for a one-month supply. The public page identifies a 15 mL bottle with a concentration of 300 mg/mL. These details make the offer more specific than a generic nasal starting price, although the actual prescription and pharmacy label should still be confirmed before purchase.

This is a separate product from the provider's NAD+ injection. The injection has four- and twelve-week package choices, while the checked nasal listing describes a one-month bottle. We do not transfer injection pricing, package periods or supply assumptions to the nasal review simply because both products come from GobyMeds.

A single purchase rather than automatic refills

The nasal offer is presented as a one-time payment without automatic renewal or a membership charge. A reader who wants to avoid a recurring commitment may find that structure relevant. Continuing treatment would still involve another supply and payment, and the conditions for that later order should be discussed with the provider.

Ask for the order terms covering clinical screening, pharmacy fulfillment and delivery. A refund if the provider finds someone medically ineligible does not necessarily describe the policy after a bottle has been prepared or shipped. The commercial advantage of a nonrecurring purchase should not be confused with an unconditional return policy for medication.

What the published specification can tell you

Bottle volume and concentration help identify what is being offered. They do not establish how much reaches a particular tissue, whether the route achieves an advertised outcome or how it compares clinically with another preparation. A concentration figure is especially unsuitable as a shortcut for claiming that a nasal bottle is equivalent to an injection package.

The product page describes online clinical review, follow-up and shipping as part of the offer. Confirm whether the final invoice includes everything required for the proposed care and whether any additional assessment is needed. We have not independently tested the consultation, evaluated its response times or received a shipped bottle from this provider.

Compounding and wellness claims

GobyMeds describes this nasal preparation as compounded and not FDA-approved. That distinction belongs beside the product name and price, not hidden behind a general statement about NAD+ biology. A prescription may be required for access, but a prescription is not the same as FDA approval or proof of effectiveness for a wellness claim.

The provider markets NAD+ around energy, focus and aging-related goals. We did not verify those outcomes for the finished nasal product. Ask what human evidence supports the proposed formulation and use, and whether that evidence actually studies nasal NAD+ rather than another route, an oral precursor or a laboratory mechanism.

Practical questions after the medical review

Before fulfillment, identify the dispensing pharmacy and request the bottle's storage conditions and beyond-use date. Shipping arrangements do not establish how long a product may remain outside those conditions. Obtain a contact and clear instructions for a damaged delivery, an unexpected product appearance or concerns that arise after starting prescribed care.

The $199 offer adds a clearly specified nasal option to the register, with an advertised one-time payment and a published bottle size. Its financial comparison is most useful against other nasal offers with known quantities and inclusions. The final decision should still account for the clinician's assessment, evidence limitations and the exact product that will be dispensed.

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. GobyMeds: NAD+ nasal spray Provider
  2. GobyMeds: longevity treatment overview Provider
  3. FDA: Compounding questions and answers Regulator